3rd Cell Therapy for Autoimmune Disease Summit
December 2-4, 2025 | Philadelphia, PA
Drive Transformative Therapeutic & Clinical Advances in Diverse Autoimmune Cell Therapies with Demonstrated Safety, Durable Efficacy & Improved Patient Accessibility to Redefine the Long-Term Management of Autoimmune Diseases
The 3rd Cell Therapy for Autoimmune Disease Summit arrives at a pivotal time, with autoimmune therapies set to shape the next wave of cell therapy innovation. As the sole meeting dedicated to advances in CAR-T, Treg, NK, and in vivo approaches, it offers a unique chance to gain comprehensive insights and successfully navigate the fast-evolving path to market.
16th World ADC London Summit
February 23 – 26, 2026 | London, UK
At World ADC London, innovation leads the way as 2026 spotlights breakthrough ADC advances, uniting global expertise to transform precision cancer treatment and elevate therapeutic impact across Europe.
World ADC London 2026 unites more than 800 senior European ADC leaders from biopharma, clinical practice, service providers, investment, and regulatory bodies to shape the next era of ADC development. This year’s programme focuses on securing ADCs as standard-of-care therapies by advancing novel payload mechanisms to overcome Topo1 resistance, improving translation of safe and effective ADCs into the clinic, and strengthening manufacturing capabilities. Join the community driving ADC innovation.
10th CAR-TCR Summit Europe
February 24 – 26, 2026 | London, UK
Bringing together leaders from across Europe and Asia, CAR-TCR Europe accelerates the development and delivery of transformative CAR-TCR therapies, advancing global collaboration to ensure patients benefit from the next generation of cellular immunotherapies.
The 10th CAR-TCR Summit Europe, held 24–26 February 2026 in London, brings together leading experts from Europe and Asia to accelerate the development of next-generation CAR and TCR cell therapies. Starting with strategic bootcamps on regulatory pathways and funding, the conference spans R&D, clinical data, and manufacturing tracks — covering novel receptor design, scale-up, automation, in-vivo cell engineering, and strategies to boost patient access and commercial viability.
Search